TORONTO, Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics
Inc. (TSX-V: SQD) (OTCQX: SQIDF), a life sciences company that
develops and commercializes proprietary technologies and products
for advanced microarray diagnostics, today announced that its
common shares have been approved for trading in the United States on the OTCQX marketplace
("OTCQX"). Trading is expected to commence on September 17, 2014 on the OTCQX under the symbol
SQIDF. The Company will continue to trade on the TSX Venture
Exchange under its existing symbol SQD.
"We are pleased to be traded on the OTCQX marketplace," said
Andrew Morris, Chief Executive
Officer of SQI Diagnostics Inc. "Trading on the OTCQX will help
increase awareness of SQI in the U.S investment community and is an
important step for SQI's continued growth."
The OTCQX marketplace is for established, investor-focused U.S.
and global companies. To qualify for OTCQX, companies must meet
high financial standards, demonstrate compliance with U.S.
securities laws, be current in their disclosure, and be sponsored
by a professional third-party advisor. Designed for
investor-focused companies, OTCQX ensures that investors and
brokers have the quality of information that's necessary to
intelligently analyze, value, and trade their securities.
U.S. investors can find information and Real-Time Level 2 quotes
for the Company on www.otcmarkets.com. Dorsey & Whitney
LLP will act as the Company's Principal American Liaison on the
OTCQX marketplace.
About SQI Diagnostics
SQI Diagnostics is a life
sciences and diagnostics company that develops and commercializes
proprietary technologies and products for advanced microarray
diagnostics. The Company's proprietary microarray tests and
fully-automated systems are designed to simplify protein and
antibody testing workflow, increase throughput, reduce costs and
provide excellent data quality. For more information, please visit
www.sqidiagnostics.com.
Forward-looking Information
This news release
contains certain forward-looking statements, including, without
limitation, statements containing the words "will", "expects",
"intends" and other similar expressions which constitute
"forward-looking information" within the meaning of applicable
securities laws. Forward-looking statements reflect the Company's
current expectation and assumptions, and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially from those anticipated. These forward-looking statements
involve risks and uncertainties including, but not limited to risks
related to the timing for the commencement of trading on the OTCQX,
the increased awareness by the U.S. investor community of the
Company, our continued listing on both the TSX Venture Exchange and
the OTCQX, the failure to obtain necessary regulatory approvals,
general economic and market segment conditions, and international
risk and currency exchange, agreements and future agreements to
sell our products, the acceleration of our revenue ramp, general
economic and market segment conditions. Such statements reflect the
current views of the Company with respect to future events and are
subject to certain risks and uncertainties and other risks detailed
from time-to-time in the Company's ongoing filings with the
securities regulatory authorities, which filings can be found at
www.sedar.com. Actual results, events, and performance may differ
materially. Readers are cautioned not to place undue reliance on
these forward-looking statements. The Company undertakes no
obligation to publicly update or revise any forward-looking
statements either as a result of new information, future events or
otherwise, except as required by applicable laws.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE SQI Diagnostics Inc.